Site-Selectively Functionalized Albumin with DFO*Maleimide for 89Zr-Radiolabeling Yields a Metabolically Stable PET Probe that Enables Late Time-Point Tumor Imaging in Mice

Human serum albumin (HSA) is a clinically validated drug carrier that improves drug delivery to tumor tissues. However, clinical imaging strategies are lacking to stratify patients who will benefit from HSA-bound drugs. In this study, we site-selectively radiolabeled HSA with zirconium-89 (89Zr), using the octadentate chelator DFO*, to provide an imaging probe with enhanced stability and sufficient half-life to elucidate the long-term (tumoral) albumin homeostasis. [89Zr]Zr-DFO*malHSA demonstrated excellent metabolic stability and high tumor uptake in a longitudinal PET study (72 h p.i.) using a subcutaneous colorectal cancer allograft model (CT26). Preliminary results also showed enhanced enrichment of the PET probe in an intraperitoneally injected CT26 model indicating the role of the EPR effect not only in subcutaneous models. Consequently, [89Zr]Zr-DFO*malHSA is a promising tool to image albumin accumulation in malignant tissues and should be further (pre)clinically developed as a companion diagnostic agent for patient stratification in trials with albumin-binding drugs.